Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial

Annals of Internal Medicine

Volumn 159, Issue 2, 2013, Pages 77-85

  Cook, Nancy R ^a   Lee, I Min ^a   Zhang, Shumin M ^a   Moorthy, M Vinayaga ^a   Buring, Julie E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; ARTICLE; ASCENDING COLON; BREAST CANCER; CANCER MORTALITY; CANCER RISK; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ASPIRIN; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PLATELET AGGREGATION INHIBITORS;

EID: 84880278340     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-2-201307160-00002     Document Type: Article

References (28)

1. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-78. [PMID: 22084361]
2. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-7. [PMID: 19410194]
3. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403-15. [PMID: 22517822]
4. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256-66. [PMID: 19211452]
5. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-50. [PMID: 20970847]
6. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41. [PMID: 21144578]
7. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-13. [PMID: 17499602]
8. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602-12. [PMID: 22440946]
9. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-601. [PMID: 22440947]
10. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47-55. [PMID: 15998890]
11. Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998;128:713-20. [PMID: 9556464]
12. Chan AT, Cook NR. Are we ready to recommend aspirin for cancer prevention? Lancet. 2012;379:1569-71. [PMID: 22440945]
13. Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study: Summary of the study design. Journal of Myocardial Ischemia. 1992;4:27-9.
14. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27. [PMID: 10718501]
15. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. [PMID: 15753114]
16. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187-220.
17. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer Publishing; 2000.
18. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70. [PMID: 10955409]
19. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2012. [PMID: 23239115]
20. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081-7. [PMID: 22036019]
21. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S. [PMID: 11157642]
22. Thun MJ. Beyond willow bark: aspirin in the prevention of chronic disease [Editorial]. Epidemiology. 2000;11:371-4. [PMID: 10874540]
23. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259-67. [PMID: 22473097]
24. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105:1107-13. [PMID: 21847126]
25. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596-606. [PMID: 23094721]
26. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209-16. [PMID: 22231610]
27. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2009;150:396-404. [PMID: 19293072]
28. Dorresteijn JA, Visseren FL, Ridker PM, Paynter NP, Wassink AM, Buring JE, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J. 2011;32:2962-9. [PMID: 22090661]